Showing 2291-2300 of 3223 results for "".
- Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results at ARVOhttps://modernod.com/news/aldeyra-therapeutics-presents-dry-eye-disease-phase-2a-clinical-trial-results-at-arvo/2480191/Aldeyra Therapeutics presented the results of a randomized, double-masked, parallel-group phase 2a dry eye disease clinical trial of topical ocular reproxalap at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting. The primary objective of the trial, to select a fo
- Allergan CEO: Large Deal Would Be An Unlikely Outcome of Reviewhttps://modernod.com/news/allergan-ceo-large-deal-would-be-an-unlikely-outcome-of-review/2480196/Allergan Chief Executive Brent Saunders said on Monday that while the company is considering large, transformational deals as part of a strategic review, they are a “very low priority and a very unlikely outcome” of the process, according to a Reuters
- Allergan Presents Data at the ARVO Annual Meeting in Honoluluhttps://modernod.com/news/allergan-presents-data-at-the-arvo-annual-meeting-in-honolulu/2480202/Allergan announced that 19 posters on their eye care offerings will be presented at this year’s ARVO meeting in Hawaii. These presentations will cover a variety of topics in various subspecialties, including ocular surface, glaucoma, and retina. Retina Post
- Lighthouse Guild Offers eLearning Course on Low Vision Assessment for Occupational Therapyhttps://modernod.com/news/lighthouse-guild-offers-elearning-course-on-low-vision-assessment-for-occupational-therapy/2480221/Lighthouse Guild, in partnership with the American Occupational Therapy Association (AOTA), is offering a 2-hour online program designed for occupational therapists in all settings. The course titled “Low Vision Assessment for Occupational Therapy” demonstrates the basic strategies and tools for
- Allergan Moves in as Shire Rebuffs $63 billion Takeda Bidhttps://modernod.com/news/allergan-moves-in-as-shire-rebuffs-63-billion-takeda-bid/2480225/Drugmaker Shire has rejected a third takeover bid worth nearly $63 billion from Japan’s Takeda Pharmaceutical, although talks are continuing, while sources said Allergan was also in competing
- Alcon Adds New Gemstone Collection to Air Optix Colors Lens Portfolio and Introduces 2-Count Packshttps://modernod.com/news/alcon-adds-new-gemstone-collection-to-air-optix-colors-lens-portfolio-and-introduces-2-count-packs/2480236/Alcon has introduced its new Air Optix Colors Gemstone Collection of color contact lenses, with three new colors – Amethyst, True Sapphire, and Turquoise. Now offering a total of 12 colors, Air Optix Colors lenses appeal to a wide range of patients and offer a strong incremental revenue potential
- Alcon Launches New Technological Enhancements to the LenSx Laserhttps://modernod.com/news/alcon-launches-new-technological-enhancements-to-the-lensx-laser/2480242/Alcon will introduce new technological enhancements to the LenSx Laser at the American Society of Cataract and Refractive Surgery (ASCRS) 2018 annual meeting taking place April 13-17 in Washington, DC. The latest enhancements will provide new indications for use of the LenSx Laser during cataract
- Alcon Introduces Preloaded Delivery System for the CyPass Micro-Stenthttps://modernod.com/news/alcon-introduces-preloaded-delivery-system-for-the-cypass-micro-stent/2480245/Alcon has announced the launch of the CyPass Ultra System designed to streamline the process of loading the CyPass Micro-Stent, a microinvasive glaucoma surgery (MIGS) device indicated for use in adult patients with mild-to-moderate primary open-angle glaucoma undergoing cataract surgery. The new
- Allergan Announces Official Launch of the TrueTear Intranasal Neurostimulation Devicehttps://modernod.com/news/allergan-announces-launch-of-the-truetear-intranasal-neurostimulation-device-at-ascrs/2480250/Allergan announced the official launch of TrueTear, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients. TrueTear, a handheld neurostimulation device with disposable tips that is inserted into the nasal cavity to
- EyePoint Pharmaceuticals Strengthens Global IP With Notices of Allowance for Two U.S. Patents Related to Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-strengthens-global-ip-with-notices-of-allowance-for-two-u-s-patents-related-to-dexycu/2480252/EyePoint Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has issued Notices of Allowance for two patents covering Dexycu, the company’s FDA-approved long-acting intraocular product for the treatment of postoperative inflammation. The first patent (U.S. patent ap